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ABSTRACT
A stability indicating reversed phase high performance liquid chromatography method was developed and validated for the determination of the antiviral drugs of nevirapine, lamivudine and zidovudine in combination drug product. The chromatographic separation
of nevirapine, lamivudine, zidovudine and eight specified impurities of thymine, thymidine, zidovudine related compound B, nevirapine
related compound A, nevirapine related compound B, salicylic acid, cytosine, lamivudine diastereomer impurity were achieved with Waters
symmetry C18 (250 mm × 4.6 mm i.d., 5 µm) column. The method was validated according to the ICH guidelines with respect to system
suitability, linearity, precision, accuracy, robustness, LOD, LOQ, selectivity and specificity. Forced degradation study was also performed
in tablet to demonstrate the stability indicating power of the optimized HPLC method. The samples were degraded in hydrogen peroxide
condition indicating that the drug product is susceptible to oxidation. Statistical analysis proves that the method can be repeated and selective for the estimation of said drugs. The method could effectively separate the drug from its degradation product hence it can be used as
a stability indicating method. This developed procedure is also applicable for the determination of instability of the drug and dissolution
behaviour of the said products in commercial products.
Key words: HPLC, stability indicating, peak purity, dissolution, validation, impurities

INTRODUCTION
Combination therapy has proved to be one of the most
effective approaches to treat HIV infection. Nevirepine is
a non-nucleoside reverse transcriptase inhibitor (NNRTI)
with activity against human immuno-deficiency virus type
1 (HIV-1) and has already been marketed for the treatment
of HIV-1 infected adults. Nevirapine is recommended for
treating HIV infections in combination with other reverse
transcriptase inhibitor such as zidovudine and lamivudine
belonging to the nucleoside analogue class of antiretroviral
drugs. Both drugs act by terminating the growth of the DNA
chain and inhibiting the reverse transcriptase enzyme of
HIV while nevirapine acts directly by inhibiting the reverse
transcriptase(1).
A detailed literature search revealed many analytical
procedures for the determination of said drugs individually
and in combination with other drugs by HPLC(2-6) and mass
spectrometry(7,8) in human plasma. Some analytical methods
have been reported in the United States Pharmacopeia (USP)
and the British Pharmacopoeia (BP) for the determination of
* Author for correspondence. Tel: +91-427-4099998;
Fax: +91-427-4099989; E-mail: drkk@sonatech.ac.in

nevirapine, lamivudine and zidovudine in bulk drugs(9,10). A
few analytical methods have been published for assay of nevirapine, lamuvidine and stavudine in combination tablet(11,12).
Weerasak Samee et al. reported an HPLC method for the
determination of nevirapine, lamivudine and stavudine in the
presence of thymine, known impurity(13). Some papers were
published for the determination of lamivudine, zidovudine
and nevirapine in combination tablet by HPLC(14,15) and
spectrophotometer(16).
There is no stability indicating assay reported yet for
the determination of nevirapine, lamivudine and zidovudine
from combination drug product. Therefore the focus in the
present study was to develop an HPLC method for the analysis of combination drug products by degrading the drugs
under various stress conditions. The selectivity of the developed method was demonstrated by analyzing eight specified
impurities in the drug product. Nevirapine, lamivudine and
zidovudine were well separated from eight specified impurities and degradation products on a reversed phase HPLC
column. The established method was validated with respect
to specificity, linearity, precision, accuracy, robustness and
ruggedness.
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MATERIALS AND METHODS

from LGC Standards (India). Salicylic acid [2-Hydroxybenzoicacid], cytosine [4-aminopyrimidine-2(1H)-one]
and thymidine [1-(2-deoxy-β-D-erythro-pentofuranosyl)-5methylpyrimidine-2,4 (1H,3H)-dione] were purchased from
Aldrich (India). Thymine impurity [5-methylpyrimidine2,4(1H,3H)-dione] was obtained from Across Organics
(India). The chemical structure of nevirapine, lamivudine,
zidovudine and their known impurities are shown in Figure 1.
Combination drug products containing lamivudine, zidovudine and nevirapine were purchased from local hospitals. Each
tablet contains 150 mg lamivudine, 300 mg zidovudine and
200 mg nevirapine. HPLC grade acetonitrile was purchased
from Rankem. Buffer materials and other chemicals were
of analytical reagent grade. High purity water, prepared by
using Millipore milli Q plus purification system, was used
throughout this study.

I. Materials and Reagents
Nevirapine [11-Cyclopropyl-4-methyl-5,11-dihydro6H-dipyrido[3,2-b:2’,3’-e][1,4]diazepin-6-one], lamivudine
[4-Amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan5-yl]pyrimidine-2(1H)-one] and zidovudine [1-(3-azido-2,3dideoxy-β-D-erythro-pentofuranosyl)-5-methylpyrimidine2,4(1H,3H)-dione] were obtained as gift samples from
pharma lab (Baddi, India). Nevirapine related compound A
[11-ethyl-4-methyl-5,11dihydro-6H-dipyridol[3,2-b:2’,3’e][1,4]diazipine-6-one], nevirapine related compound B
[4-methyl-5,11dihydro-6H-dipyridol[3,2-b:2’,3’-e][1,4]
diazipine-6-one], lamivudine resolution mixture containing
lamivudine and diastereomer impurity and zidovudine related
compound B [3’-chloro-3’-deoxythymidine] were purchased
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Figure 1. The structures of nevirapine (a), lamivudine (b), zidovudine (c), nevirapine related compound A (d), nevirapine related compound B (e),
salicylic acid (f), diastereomer impurity (g), thymidine (h), cytosine (i), thymine (j) and zidovudine related compound B (k).
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II. Instrumentation and Conditions

V. Specificity and Selectivity

LC system was equipped with a 2695 separation module
and a 996 photo diode array detector (Waters Corporation,
Milford, USA). Empower software build-2154 work station
was employed for data collection and processing.
The chromatographic separation was attained using a
Waters symmetry C18 (250 mm × 4.6 mm i.d., 5 µm) column.
The gradient mobile phase mode was used for the separation. The initial mobile phase solution consisted of 0.025
M ammonium acetate buffer (pH 4.2 adjusted with glacial
acetic acid) and methanol [95/5 (v/v)]. This composition was
maintained up to 15 min and gradually increased to 55% of
methanol at 30 min and it was maintained up to 38 min. The
gradient was further increased to 85% of methanol at 42 min,
maintained up to 46 min and gradually decreased to 5% of
methanol at 50 min. The flow rate was 1.0 mL/min and the
column temperature was 30°C. The absorbance was monitored at 270 nm. The mobile phase was filtered through a
0.45 µm Millipore filter and degassed before delivering into
the system.
Labindia 2000 dissolution apparatus was used for the
dissolution sample preparation. Dissolution testing was
performed in compliance with USP (711) using apparatus 2.
A paddle speed of 50 rpm was selected for the study.

Specificity is the ability of the method to measure the
analyte response in the presence of sample matrix and the
specified impurities. Stress studies were performed in drug
product to provide an indication of stability and specificity of
the proposed method. Intentional degradation was attempted
to stress conditions of heat (80°C), light at 254 nm, acid
(0.1 N HCl), base (0.1 N NaOH) and peroxide (3% H2O2).
Study period was 2 days for heat and light, 4 hrs for the acid,
base and oxidation. Peak purity test was carried out for nevirapine, lamivudine and zidovudine by using PDA detector
in stressed samples. The assay studies were carried out for
stressed samples against standard. The assays were also
performed in combination drug product by analyzing nevirapine impurities, namely related compound A and related
compound B, lamivudine impurities, namely cytosine and
salicylic acid, zidovudine impurities, namely thymine,
thymidine and related compound B, at 1.0% level.

III. Standard Preparation
A standard solution of nevirapine, lamivudine and
zidovudine at the target concentration of 40, 30 and 60
µg/mL respectively was prepared by transferring 40 mg, 30
mg and 60 mg of each standard into a 100 mL volumetric
flask containing about 20 mL methanol. The solution was
sonicated for 30 min or until the solid was completely
dissolved and the volumetric flask was made up to the
mark with acetate buffer solution (pH 4.2). Five mL of the
resulting solution was further diluted to 50 mL with the
diluent [mixture of methanol : acetate buffer (pH 4.2); 2 :
8 (v/v)] and mixed thoroughly prior to use. USP lamivudine
resolution mixture containing lamivudine and diastereomer
impurity is used for system suitability check.
IV. Sample Preparation
Twenty tablets were weighed and crushed into fine
powder. Powder equivalent to 40 mg of nevirapine was
weighed and transferred to a 100 mL volumetric flask and
20 mL methanol was added. The resulting solution was
sonicated for 30 min, cooled and made to the mark with
acetate buffer solutions (pH 4.2). Five mL of the resulting
solution was further diluted to 50 mL with diluent [mixture
of methanol : acetate buffer 2 : 8 (v/v)] and mixed thoroughly
prior to use. The concentrations of nevirapine, lamivudine
and zidovudine were 40, 30 and 60 µg/mL, respectively.
This sample preparation was used for the quantification of
nevirapine, lamivudine and zidovudine.

VI. Validation
The method was validated according to International
Conference of Harmonization(17) and United States Pharmacopeia(9). The following validation parameters are addressed:
linearity, accuracy, precision, specificity, selectivity, ruggedness and robustness.

RESULTS AND DISCUSSION
I. Optimization of Chromatographic Condition
The main objective of the chromatographic method
is to separate nevirapine, lamivudine and zidovudine from
their specified impurities and other sample matrix. Gradient
system is preferred to achieve improved peak shape and
resolution. In isocratic system nevirapine and its impurities
were eluted late. Hence, it was decided to use gradient HPLC
mode under gradient programme. The buffer pH was chosen
based on the pKa values of nevirapine (3.31), lamivudine
(9.36) and zidovudine (2.42). The HPLC separation was
achieved at 30°C with acetate buffer (pH 4.2). The monitoring wavelength was set at 270 nm in which all the drug
substances, namely nevirapine, lamivudine and zidovudine,
gave good response. Resolution between lamivudine and
diastereomer impurity was found 1.32, as shown in the chromatogram in Figure 2. System suitability results were shown
in Table 1. Resolutions more than 1.3 were found between
major compounds and close eluting impurities. The developed HPLC method was found to be specific and selective
for quantification of nevirapine, lamivudine and zidovudine
in combination drug product. To our knowledge this is the
first method developed to analyze eight specified impurities
in the drug product containing lamivudine, zidovudine and
nevirapine.
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II. Results of Forced Degradation Study
Stress studies of the drug product were utilized for the
identification of the possible degradation products and for
the validation of the stability-indicating analytical procedure.
During the forced degradation study, significant degradation
was observed in oxidative condition and a major unknown
impurity was observed. In hydrolysis condition, thymine
impurity was formed as the major degradient. The degradation chromatograms were shown in Figure 3. The chromatograms were examined for the appearance of extra peaks. Peak
purity of the samples under stressed conditions was verified
by using a photodiode array detector. The purity of the principal peaks was found satisfactory. This study confirmed the
stability indicating power of the optimized HPLC method.
Peak purity results indicated that nevirapine, lamivudine and

zidovudine peaks are homogeneous and pure in all analysed
stress samples. To demonstrate the specificity of the method,
drug product was spiked with specified impurities of nevirapine, lamivudine and zidovudine and was analysed against
the standard. The peak purity result of impurity spiked sample
was found satisfactory and the assays of spiked and unspiked
samples were found the same. Chromatograms were shown
in Figure 4. The results obtained from the forced degradation
studies were summarized in Table 2.
III. Method Validation
(I) Precision
The RSD values of nevirapine, lamivudine and zidovudine during the method precision and intermediate precision

Table 1. Results of system suitability parameter
Compound

RT (min)

USP tailing
Factor

Theoretical
Plates

USP resolution
(For close eluting impurity)

Lamivudine

13.4

1.07

8201

Lamivudine and diastereomer impurity-1.32

Zidovudine

24.0

1.13

72325

Zidovudine and zidovudine related compound B-2.66

Nevirapine

33.0

1.10

95543

Nevirapine and nevirapine related compound B-4.82

b

0.06

AU0.04

0.02

g
0.00
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Figure 2. System suitability chromatogram contains lamivudine diasteriomer impurity (g) and lamivudine (b).
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Figure 3. Chromatogram of acid, base and peroxide stressed sample (peak b- lamivudine, peak c- zidovudine and peak a- nevirapine, peak
j-thymine, peak e- nevirapine related compound B, d- nevirapine related compound A).
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study were within 1.0% and well within the generally acceptable limit of 2% confirming good precision.
The precision of the impurity method was checked by
injecting six individual preparations of lamivudine, zidovudine and nevirapine spiked with 0.15% zidovudine impurity,
nevirapine impurity,and lamivudine impurity to the target
analyte concentration (i.e., 40 µg/mL of nevirapine, 30 µg/
mL of lamivudine and 60 µg/mL of zidovudine).
T h e
RSDs of thymine, thymidine, zidovudine related compound
B, nevirapine related compound A, nevirapine related
compound B, salicylic acid and cytosine were found less than
5%, and intermediate precision was obtained to be less than
5% for all impurities. The precision results confirmed good
reproducibility of the method.

0.40

(II) Limit of Quantification (LOQ) and Limit of Detection
(LOD)
Limit of quantification (LOQ) and limit of detection
(LOD) for the impurities were established at signal-to-noise
ratios (S/N) of 10 : 1 and 3 : 1, respectively by injecting a
series of diluted solutions of known concentration. Precision
was performed at the LOQ level by analysing six individual
preparations of all impurities and calculating the RSD of
peak area for each compound.
The RSD of all impurities at the LOQ concentrations
was found less than 7.5%. The individual LOD and LOQ of
impurities were shown in Table 3.

Impurity Spiked
Sample

0.30

Blank
AU0.20
0.10

a
b
i

j

h

a

k

f

d
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40.00
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Minutes

Figure 4. Overlay chromatogram of blank and impurity spiked sample (peak i- cytosine, peak j-thymine, peak h- thymidine, peak b- lamivudine,
peak f- salicylic acid, peak c– zidovudine, peak k-zidovudine related compound B, peak e- nevirapine related compound B, peak a- nevirapine, peak
d- nevirapine related compound A).

Table 2. Summary of forced degradation results
Condition

% Assay of Nevirapine

% Assay of Lamivudine

% Assay of Zidovudine

Unstressed sample

99.2

99.0

101.1

Acid hydrolysis (0.1 N HCL)

97.0

95.2

87.3

Base hydrolysis (0.1 N NaOH)

96.9

93.3

95.7

Oxidation (3% H2O2)

95.3

80.3

98.5

101.2

99.2

99.5

Light (254 nm)

99.3

100.3

99.2

Impurities spiked sample

99.0

99.3

99.5

Heat (80°C)

Table 3. LOQ and LOD of impurities by signal- to- noise ratio method

a

Impurity

LOD (% with respect to
test concentration)a

LOQ (% with respect to
test concentration) a

RSD of LOQ (%), n = 6

Thymine

0.01

0.02

3.3

Thymidine

0.01

0.03

3.5

Zidovudine related compound B

0.01

0.03

4.5

Nevirapine related compound A

0.01

0.04

4.8

Nevirapine related compound B

0.01

0.03

3.5

Salicylic acid

0.01

0.04

3.9

Cytosine

0.01

0.03

4.9

Concentration details - 40 µg/mL of nevirapine, 30 µg/mL of lamivudine and 60 µg/mL of zidovudine.
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Table 4. Linearity data for drug substance and its impurities
Compound

Range (µg/mL)

Regression parameters (n = 3)
Equation of regression line

R2 value

Nevirapine

20 - 60

Y = 46433x + 4000.2

0.9999

Lamivudine

15 - 45

Y = 77572x – 38195

0.9999

Zidovudine

15 - 90

Y = 64890x – 6600

0.9993

Cytosine

0.01 - 0.14

Y = 22147x + 21.977

0.9991

Thymine

0.01 - 0.27

Y = 41418x – 47.138

0.9994

Thymidine

0.02 - 0.27

Y = 29808x + 80.708

0.9997

Slicylic acid

0.01 - 0.14

Y = 20624x + 29.113

0.9993

Zidovudine related compound B

0.02 - 0.27

Y = 32762x + 23.632

0.9992

Nevirapine related compound B

0.02 - 0.18

Y = 23778x – 76.85

0.9994

Nevirapine related compound A

0.01 - 0.18

Y = 18608x + 75.814

0.9995

(III) Linearity
To measure the linearity of the assay, standard solutions
were prepared containing 50 to 150% of the analyte concentration of 40 µg/mL (i.e., 20, 30, 40, 50 and 60 µg/mL) for
nevirapine, 30 µg/mL (i.e., 15, 22.5, 30, 37.5 and 45 µg/mL)
for lamivudine and 60 µg/mL (i.e., 30, 45, 60, 75 and
90 µg/mL) for zidovudine. Linearity test solutions for the
impurity method were prepared by diluting the impurity
stock solution to the required concentrations. The solutions
were prepared at seven concentrations ranging from the
LOQ to 300% impurity specification level of 0.15% (i.e.,
LOQ, 0.075, 0.11, 0.15, 0.225, 0.3 and 0.45%). To establish
the linearity, triplicate preparations were tested. Peak area
versus concentration data were subjected to least - squares
linear regression analysis. The correlation coefficients for
the calibration plots were thus calculated.
The linearity plot for the drug substances and impurities
were obtained over the ranges tested. As shown in Table 4
an excellent correlation existed between the peak areas and
concentration of the analytes.
(IV) Accuracy
The recovery studies were carried out by spiking the
standard solution of nevirapine, lamivudine and zidovudine
to the already analysed samples of the tablet. The recovery
of three sample preparations at five concentration levels (i.e.,
110, 120, 130, 140 and 150%) was examined. The recovery
study of impurities were carried out in triplicate at LOQ,
0.075, 0.11, 0.15, 0.225, 0.3 and 0.45% of target analyte
concentration (i.e., 40 µg/mL of nevirapine, 30 µg/mL of
lamivudine and 60 µg/mL of zidovudine). The percentages
of recoveries for impurities were calculated from impurity
standard curves.
The proposed method, when used for extraction and
subsequent estimation of nevirapine, lamivudine and zidovudine from pharmaceutical dosage form after injecting with
10, 20, 30, 40 and 50% of additional drug, gave recovery

Table 5. Accuracy of the developed RP-HPLC method
Excess drug added to the
analyte (%) n = 3

% Recovered
Nevirapine Lamivudine Zidovudine

Level 1 (10%)

99.0

99.8

99.2

Level 2 (20%)

99.2

100.1

98.9

Level 3 (30%)

100.9

99.7

100.2

Level 4 (40%)

101.1

99.1

98.9

Level 5 (50%)

98.5

100.1

101.1

Mean % recovery (n = 15)

99.7

99.8

99.7

1.2

0.4

1.0

% RSD

range from 98.5 to 101.1%. The RSDs are well within the
limit of 2.0%. The results were shown in Table 5. The mean
recoveries and RSDs of individual impurities ranged from
95.2 to 104.5% and 1.8 to 4.5%, respectively, and these accuracy results were found satisfactory.
(V) Robustness
To determine the robustness of the method, experimental conditions were altered to analyze standard and
sample solutions. The flow rate was varied by ± 0.1 mL/
min i.e., 0.9 mL/min and 1.1 mL/min. Column temperature
was varied by ± 2°C i.e., 28°C and 32°C and ±5% change of
organic solvent. The wavelength was varied by ± 2 nm i.e.,
268 nm and 272 nm. The RSD of standard was found within
1.0% and the assay of lamivudine, nevirapine and zidovudine
gave results between 98 - 102%. The resolution among all
closely eluting impurity peaks was found greater than 1.2.
These deliberate changes did not affect the assay value and
resolution among close eluting impurity.
(VI) Market Sample Analysis
The method was applied for the determination of nevirapine, lamivudine and zidovudine in market sample tablets
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Table 6. Results of analysis of market sample tablets
Formulation

Drug

Mean (%)

RSD (%)

ZIDOLAM-N

Nevirapine

99.3

0.9

(Manufactured by

Lamivudine

99.5

0.6

Hetero )

Zidovudine

98.9

0.5

CYTOCOM-N

Nevirapine

98.7

0.7

(Manufactured by

Lamivudine

100.3

0.8

Alkem)

Zidovudine

99.5

0.9

(150 mg of Lamivudine, 300 mg of Zidovudine and 200 mg
of Nevirapine). The proposed method was verified by means
of six replicated estimations of pharmaceutical preparations.
Satisfactory results were obtained for the recovery of three
drugs (between 98 and 102%) and were in good agreement with the label claims (Table 6). The low value of RSD
indicated that the method is precise. The impurity level is
determined in ZIDOLAM-N tablet. Thymine, lamivudine
diasteriomer, nevirapine related compound B, and nevirapine
related compound C were found in the level of 0.08, 0.05,
0.04 and 0.04%, respectively in the total tablet.
The developed method also applied for the dissolution
study of combination tablet. Food and Drug Administration of United States recommended dissolution condition of
900 mL 0.01 N HCL for 60 min for lamivudine, zidovudine
and nevirapine combination tablet(18). Six tablet units were
used for the dissolution sample preparation. Auto sampling
was performed using 10 mL of aliquots. These solutions were
immediately filtered through Millipore nylon 0.45 µm filter.
The first 2 mL of sample was discarded prior to collecting
the sample for analysis. The average percentage release of
six tablet units were found 97.5% for lamivudine, 98.2% for
zidovudine and 98.3% for nevirapine with RSD values of less
than 5.0%.

CONCLUSIONS
The reversed phase liquid chromatography method for
the determination of nevirapine, lamivudine and zidovudine
is precise, accurate, linear, rugged, robust, selective and
specific. The method was validated showing satisfactory data
for tested parameters. The developed method is a stability
indicating one and can be conveniently used in the quality
control department to assay, related substances and dissolution of nevirapine, lamivudine and zidovudine in regular
production and stability samples.
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